

Table S1. Baseline characteristics and dosimetry data of the TS-matched cohort.

| Variables | VS | TS | <i>p</i> -value |
|--------------------------------|--------------|-------------|-----------------|
| Patients (tumors), n | 19 | 19 | |
| Age at SRS, years | 50.5 ± 14.7 | 50.1 ± 15.4 | 0.930 |
| Observation period, months | 102.8 ± 87.3 | 91.5 ± 82.4 | 0.737 |
| Target volume, cm ³ | 4.0 ± 2.5 | 3.9 ± 2.4 | 0.930 |
| Prescription dose, Gy | 13.7 ± 2.4 | 14.1 ± 1.5 | 0.141 |
| Central dose, Gy | 28.3 ± 4.6 | 29.4 ± 5.0 | 0.403 |
| Male | 8 (42.1) | 8 (42.1) | 1.000 |
| Surgical history | 3 (15.7) | 3 (15.7) | 1.000 |

Data are reported as mean ± standard deviation or n (%) unless otherwise stated. VS, vestibular schwannoma; TS, trigeminal schwannoma; SRS, stereotactic radiosurgery.

Table S2. Baseline characteristics and dosimetry data of the FS-matched cohort.

| Variables | VS | FS | <i>p</i> -value |
|--------------------------------|-------------|-------------|-----------------|
| Patients (tumors), n | 7 | 7 | |
| Age at SRS, years | 60.6 ± 4.9 | 61.6 ± 12.7 | 0.949 |
| Observation period, months | 72.5 ± 58.2 | 85.5 ± 49.9 | 0.848 |
| Target volume, cm ³ | 1.7 ± 1.9 | 1.7 ± 1.9 | 0.898 |
| Prescription dose, Gy | 12.6 ± 1.0 | 12.9 ± 2.3 | 0.656 |
| Central dose, Gy | 26.0 ± 2.6 | 25.3 ± 6.1 | 0.494 |
| Male | 2 (28.6) | 2 (28.6) | 1.000 |
| Surgical history | 3 (42.9) | 3 (42.9) | 1.000 |

Data are reported as mean ± standard deviation or n (%) unless otherwise stated. VS, vestibular schwannoma; FS, facial schwannoma; SRS, stereotactic radiosurgery.

Table S3. Baseline characteristics and dosimetry data of the JFS-matched cohort.

| Variables | VS | JFS | <i>p</i> -value |
|--------------------------------|-------------|-------------|-----------------|
| Patients (tumors), n | 18 | 18 | |
| Age at SRS, years | 48.3 ± 16.4 | 47.9 ± 18.6 | 0.825 |
| Observation period, months | 79.5 ± 96.4 | 43.9 ± 37.0 | 0.311 |
| Target volume, cm ³ | 4.3 ± 5.3 | 4.1 ± 3.7 | 0.849 |
| Prescription dose, Gy | 13.2 ± 2.3 | 13.6 ± 1.0 | 0.038* |
| Central dose, Gy | 27.1 ± 4.9 | 28.9 ± 3.3 | 0.098 |
| Male | 8 (44.4) | 8 (44.4) | 1.000 |
| Surgical history | 11 (61.1) | 11 (61.1) | 1.000 |

* $p < 0.05$ is considered statistically significant. Data are reported as mean ± standard deviation or n (%) unless otherwise stated. VS, vestibular schwannoma; JFS, jugular foramen schwannoma; SRS, stereotactic radiosurgery.

Table S4. Summary of radiation-induced adverse events after SRS in TS matched cohort.

| Variables | VS | TS | <i>p</i> -value |
|---------------------------|---------|---------|-----------------|
| Number of cases with RAEs | 1 (5.3) | 1 (5.3) | 1.000 |
| Trigeminal neuralgia | 0 (0.0) | 0 (0.0) | N/A |
| Facial palsy | 1 (5.3) | 0 (0.0) | 0.311 |
| Lower palsy | 0 (0.0) | 0 (0.0) | N/A |
| Hydrocephalus | 1 (5.3) | 1 (5.3) | 1.000 |
| CTCAE grade 3–4 | 1 (5.3) | 1 (5.3) | 1.000 |

All events occurred in the same case. VS, vestibular schwannoma; TS, trigeminal schwannoma; RAEs; radiation-induced adverse events; CTCAE, Common Terminology Criteria for Adverse Events version 5.0; N/A, not applicable.

Table S5. Summary of radiation-induced adverse events after SRS in FS matched cohort.

| Variables | VS | FS | <i>p</i>-value |
|---------------------------|-----------|-----------|-----------------------|
| Number of cases with RAEs | 0 (0.0) | 0 (0.0) | N/A |
| Trigeminal neuralgia | 0 (0.0) | 0 (0.0) | N/A |
| Facial palsy | 0 (0.0) | 0 (0.0) | N/A |
| Lower palsy | 0 (0.0) | 0 (0.0) | N/A |
| Hydrocephalus | 0 (0.0) | 0 (0.0) | N/A |
| CTCAE grade 3–4 | 0 (0.0) | 0 (0.0) | N/A |

VS, vestibular schwannoma; FS, facial schwannoma; RAEs; radiation-induced adverse events; CTCAE, Common Terminology Criteria for Adverse Events version 5.0; N/A, not applicable.

Table S6. Summary of radiation-induced adverse events after SRS in JFS matched cohort.

| Variables | VS | JFS | <i>p</i> value |
|---------------------------|-----------|------------|-----------------------|
| Number of cases with RAEs | 2 (11.1) | 1 (5.6) | 0.547 |
| Trigeminal neuralgia | 0 (0.0) | 0 (0.0) | N/A |
| Facial palsy | 1 (5.6) | 0 (0.0) | 0.311 |
| Lower palsy | 0 (0.0) | 0 (0.0) | N/A |
| Hydrocephalus | 2 (11.1) | 1 (5.6) | 0.547 |
| CTCAE grade 3–4 | 2 (11.1) | 0 (0.0) | 0.146 |

VS, vestibular schwannoma; JFS, jugular foramen schwannoma; RAEs; radiation-induced adverse events; CTCAE, Common Terminology Criteria for Adverse Events version 5.0; N/A, not applicable.